Gregory Grabowski, MD
Professor Emeritus
Department of Pediatrics
University of Cincinnati College of Medicine
Division of Human Genetics
Cincinnati Children’s Hospital Medical Center
3333 Burnet Avenue
Cincinnati, Ohio 45229-3039
Chief Scientific Officer
Kiniksa Pharmaceuticals, Ltd.
15 Walnut St., Suite 200
Wellesley, MA 02481
Dr. Grabowski’s Early Career
Dr. Grabowski received his MD from the University of Minnesota, where he also completed his residency in pediatrics and fellowship training in human genetics. He established research and clinical programs at the same institution before moving to New York City and the Mount Sinai School of Medicine in 1979.
At Mount Sinai, he developed the world’s largest clinic for patients with Gaucher disease and other lysosomal diseases. He established basic research and diagnostic laboratories for genetic diseases as well as the first treatment center for enzyme therapy in Gaucher disease.
Dr. Grabowski’s Later Accomplishments
After 13 productive years, the Cincinnati Children’s Hospital Research Foundation recruited him as the A. Graeme Mitchell Chair of Human Genetics and director of human genetics (DHG). He also was professor in the departments of molecular genetics and biochemistry, and pediatrics, at the University of Cincinnati College of Medicine. In these positions, he created the clinical, educational, diagnostic, and research foundations for the DHG and its roughly 30 faculty members.
During his career, he published more than 320 scholarly works on lysosomal storage and genetic diseases while maintaining active treatment programs for genetic diseases. He has served with:
- Committees for the National Institutes of Health (NIH) as well as national and state governments
- Philanthropic foundations like the Project Hope Gaucher Disease Initiative
- American Society for Clinical Investigation
- American Association of Physicians
- Editorial board of Molecular Genetics and Metabolism
- President of the Society for Inherited Metabolic Diseases
Dr. Grabowski’s Recent Work
After more than 21 years at Cincinnati Children’s Hospital Medical Center, Dr. Grabowski joined biopharmaceutical company Synageva BioPharma in 2014. As chief scientific officer, Dr. Grabowski continued his pursuit of therapies for rare, devastating and inherited diseases.
After Alexion acquired Synageva in June 2015, he now holds the position of professor emeritus of pediatrics and genetics at the Cincinnati Children’s Hospital Research Foundation. He is on the scientific advisory boards of several biotech companies, and is chief scientific officer of Kiniksa Pharmaceuticals. His continuing passion is to discover and develop specific treatments for inherited diseases.
